Adicet Bio
ACET
41 hedge funds and large institutions have $100M invested in Adicet Bio in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 40 → 41 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.37% → 0.37% (+0%)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
43% less capital invested
Capital invested by funds: $177M → $100M (-$76.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.91M |
| 2 |
SCM
Segantii Capital Management
Hong Kong
|
+$3.08M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$270K |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$262K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.52M |
| 2 |
DAM
Deltec Asset Management
New York
|
-$1.71M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.18M |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$751K |
| 5 |
Goldman Sachs
New York
|
-$647K |
ACET Hedge Fund Activity: Q4 2018 in Review
41 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2018, worth a combined $100M — down 43% from $177M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ACET positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $3.91M. The largest seller was Millennium Management, exiting entirely with an estimated $3.52M sold.
- 41 institutional investors held Adicet Bio (ACET) as of Q4 2018, up from 40 in Q3 2018.
- Funds reported $100M of Adicet Bio stock for Q4 2018, down 43% quarter-over-quarter.
- 5 funds opened new Adicet Bio positions in Q4 2018 and 4 closed out, a net change of +1 holder.
- The largest Adicet Bio buyer in Q4 2018 was BlackRock, an estimated $3.91M added.
- The largest Adicet Bio seller in Q4 2018 was Millennium Management, an estimated $3.52M sold.
Based on aggregated 13F filings for Q4 2018.